Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Finished Goods (2023 - 2025)

Historic Finished Goods for 60 Degrees Pharmaceuticals (SXTP) over the last 3 years, with Q2 2025 value amounting to $208195.0.

  • 60 Degrees Pharmaceuticals' Finished Goods rose 7499.35% to $208195.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $208195.0, marking a year-over-year increase of 7499.35%. This contributed to the annual value of $157881.0 for FY2024, which is 1565.37% down from last year.
  • As of Q2 2025, 60 Degrees Pharmaceuticals' Finished Goods stood at $208195.0, which was up 7499.35% from $143161.0 recorded in Q1 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Finished Goods ranged from a high of $208195.0 in Q2 2025 and a low of $84449.0 during Q3 2024
  • Moreover, its 3-year median value for Finished Goods was $156390.0 (2024), whereas its average is $150890.1.
  • Per our database at Business Quant, 60 Degrees Pharmaceuticals' Finished Goods crashed by 1565.37% in 2024 and then skyrocketed by 7499.35% in 2025.
  • Quarter analysis of 3 years shows 60 Degrees Pharmaceuticals' Finished Goods stood at $187182.0 in 2023, then dropped by 15.65% to $157881.0 in 2024, then surged by 31.87% to $208195.0 in 2025.
  • Its Finished Goods was $208195.0 in Q2 2025, compared to $143161.0 in Q1 2025 and $157881.0 in Q4 2024.